Barrett's esophagus: Progression to adenocarcinoma and markers

Annals of the New York Academy of Sciences

Volumn 1232, Issue 1, 2011, Pages 210-229

  Fang, Dianchun ^a   Das, Kiron M ^b   Cao, Weibiao ^c   Malhotra, Usha ^d   Triadafilopoulos, George ^e   Najarian, Robert M ^f   Hardie, Laura J ^g   Lightdale, Charles J ^h   Beales, Ian L P ⁱ   Felix, Valter Nilton ^j   Schneider, Paul M ^k   Bellizzi, Andrew M ^l  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h New York Presbyterian Hospital Columbia University Medical Center   (United States)

ⁱ NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^j Medical School   (Brazil)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

Acid exposure; Aneuploidy; Barrett's esophagus; Bile exposure; Carcinoma; Cdx2 mRNA expression; Claudin 4; Confocal laser endomicroscopy; COX2; Cyclooxygenase 2 inhibitors; ECLE; GERD; Hydroxymethyl CoA reductase inhibitors; In vitrotransformation; Morphological changes; Neoplastic progression; NOX5; P16; P53 protein; PCLE; Phenotype changes; Protein farnesyltransferase; Squamous epithelium; Tetraploidy

Indexed keywords

BILE ACID; BILE SALT; BIOLOGICAL MARKER; CELECOXIB; CLAUDIN 4; CYCLOOXYGENASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVINOLIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PRAVASTATIN; PROTEIN NOX5 S; PROTEIN P16; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIMVASTATIN; SOMATOMEDIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CELL CYCLE REGULATION; CONFOCAL LASER MICROSCOPY; DISEASE COURSE; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; DRUG POTENTIATION; EPITHELIUM CELL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL PH MONITORING; GASTROESOPHAGEAL REFLUX; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MUTATION; PHENOTYPE; PROTEIN EXPRESSION; SQUAMOUS EPITHELIUM; STROMA CELL; UPREGULATION;

EID: 80053184157     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06053.x     Document Type: Article

References (58)

1. Matsuda, M., A. Kubo, M. Furuse & S. Tsukita 2004. A peculiar internalization of claudins, tight junction- specific adhesion molecules, during the intercellular movement of epithelial cells. J. Cell. Sci. 117(Pt 7): 1247-1257.
2. Gyõrffy, H., A. Holczbauer, P. Nagy, et al 2005. Claudin expression in Barrett's esophagus and adenocarcinoma. Virchows. Arch. 447: 961-968.
3. Montgomery, E., A.J. Mamelak, M. Gibson, et al 2006. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl. Immunohistochem. Mol. Morphol. 14: 24-30.
4. Tobey, N.A., S.S. Hosseini, C.M. Argote, et al 2004. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am. J. Gastroenterol. 99: 13-22.
5. Calabrese, C., A. Fabbri, M. Bortolotti, et al 2003. Dilated intercellular spaces as a marker of esophageal damage: comparative results in gastro-esophageal reflux disease with or without bile reflux. Aliment. Pharmacol. Ther. 18: 525-532.
6. Wang, K.K. & R.E. Sampliner 2008. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am. J. Gastroenterol. 103: 788-797.
7. Das, K.M., Y. Kong, M. Bajpai, et al 2011. Transformation of benign Barrett's epithelium by repeated acid and bile exposure over 65 weeks: a novel in vitro model. Intl. J. Cancer 128: 274-282.
8. Das, K.M., S. Sakamaki, M. Vecchi & B. Diamond 1987. The production and characterization of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: cellular localization of the antigen by using the monoclonal antibody. J. Immunol. 139: 77-84.
9. Bajpai, M., J. Liu, X. Geng, et al 2008. Repeated exposure to acid and bile selectively induces colonic phenotype expression in a heterogenous Barrett's epithelial cell line. Lab. Invest. 88: 643-651.
10. Lin, J.L.-C., X. Geng, S. Das-Bhattacharya, et al 2002. Isolation and sequencing of a novel tropomyosin isoform preferentially associated with colon cancer. Gastroenterology 123: 152-162.
11. Lambeth, J.D. 2004. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4: 181-189.
12. Hong, J., M. Resnick, J. Behar, et al Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. Am. J. Physiol. Gastrointest. Liver Physiol. 299: G697-G706.
13. Fu, X., D.G. Beer, J. Behar, et al 2006. cAMP-response element-binding protein mediates acid-induced NADPH oxidase NOX5-S expression in Barrett esophageal adenocarcinoma cells. J. Biol. Chem. 281: 20368-20382.
14. Si, J., X. Fu, J. Behar, et al 2007. NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells. J. Biol. Chem. 282: 16244-16255.
15. Kawamata, Y., R. Fujii, M. Hosoya, et al 2003. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278: 9435-9440.
16. Bian, Y.S., M.C. Osterheld, C. Fontolliet, et al 2002. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 122: 1113-1121.
17. Klump, B., C.J. Hsieh, K. Holzmann, et al 1998. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 115: 1381-1386.
18. Schulmann, K., A. Sterian, A. Berki, et al 2005. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24: 4138-4148.
19. Jin, Z., Y. Cheng, W. Gu, et al 2009. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res. 69: 4112-4115. Epub 2009 May 12.
20. Hao, Y., G. Triadafilopoulos, P. Sahbaie, et al 2006. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology 131: 925-933.
21. Saadi, A., N.B. Shannon, P. Lao-Sirieix, et al 2010. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc. Natl. Acad. Sci. U S A 107: 2177-2182.
22. Barrett, M.T., C.A. Sanchez, L.J. Prevo, et al 1999. Evolution of neoplastic cell lineages in Barrett's esophagus. Nat. Genet. 22: 106-109.
23. Reid, B.J., L.J. Prevo, P.C. Galipeau, et al 2001. Predictors of progression in Barrett's esophagus II: baseline 17 p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol. 96: 2839-2848.
24. Sikkema, M., M. Kerkof, E.W. Steyerburg, et al 2009. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am. J. Gastroenterol. 104: 2673-2680.
25. Rabinovitch, P.S., G. Longton, P.L. Blount, et al 2001. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am. J. Gastroenterol. 96: 3071-3083.
26. Leedham, S.J., S.L. Preston, S.A. McDonald, et al 2008. Individual crypt heterogeneity and the origin of metaplastic epithelium in human Barrett's esophagus. Gut 57: 1041-1048.
27. Iravani, S., H.Q. Zhang, Z.Q. Yuan, et al 2003. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-X-L protein expression during the progression of Barrett's neoplasia. Human Pathol. 34: 975-982.
28. Di Martino, E., C.P. Wild, O. Rotimi, et al 2006. IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett's oesophagus and esophageal adenocarcinoma: potential biomarkers of disease risk. Biomarkers 11: 547-561.
29. Siahpush, S.H., T.L. Vaughan, J.N. Lampe, et al 2007. Longitudinal study of insulin-like growth factor, insulin- like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus. Cancer Epidemiol. Biomarkers Prevent. 16: 2387-2395.
30. McElholm, A.R., A.J. McKnight, C.C. Patterson, et al 2010. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. Gastroenterology 139: 204-212.
31. Feagins, L.A., N. Susnow, H.Y. Zhang, et al 2006. Gain of allelic gene expression for IGF-II occurs frequently in Barrett's esophagus. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G871-G875.
32. Kiesslich, R., L. Gossner, M. Goetz, et al 2006. In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin. Gastroenterol. Hepatol. 4: 979-987.
33. Wallace, M.B. & P. Fockens 2009. Probe-based confocal laser endomicroscopy. Gastroenterology 136: 1509-1513.
34. Dunbar, K.B., P. Okolo, III, E. Montgomery & M.I. Canto 2009. Confocal laser endomicroscopy in Barrett's esophagus and endoscopically in apparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest. Endosc. 70: 645-654.
35. Pohl, H., T. Rosch, M. Vieth, et al 2008. Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus. Gut 57: 1648-1653.
36. Sharma, P., A. Meining, E. Coron, et al 2010. Detection of neoplastic tissue in Barrett's esophagus with in vivo probe-based confocal endomicroscopy (DONT BIOPCE). Final results of a prospective international randomized controlled trial: image-guided versus 4-quadrant random biopsies (Abstract) Digestive Disease Week 2010 #1071.
37. Van Der Burgh, A., J. Dees, W. Hop & M. Van Blankenstein 1996. Esophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 39: 5-8.
38. Ogunwobi, O.O. & I.L. Beales 2008. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am. J. Gastroenterol. 103: 825-837.
39. Beales, I.L. & O.O. Ogunwobi 2010. Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in esophageal adenocarcinoma cells without affecting endothelial prostacyclin production. Int. J. Cancer 126: 2247-2255.
40. Hippisley-Cox, J. & C. Coupland 2010. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340: c2197.
41. Nguyen, D.M., P. Richardson & H.B. El-Serag 2010. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 138: 2260-2266.
42. Risques, R.A., T.L. Vaughan, X. Li, et al 2007. Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol., Biomarkers. Prev. 16: 2649-2655.
43. Xing, J., J.A. Ajani, M. Chen, et al 2009. Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev. Res. 2: 459-465.
44. Buttar, N.S., K.K. Wang, T.J. Sebo, et al 2001. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120: 1630-1639.
45. Wang, K.K., M. Wongkeesong & N.S. Buttar 2005. American Gastroenterological Association Technical Review on the role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 128: 1471-1505.
46. Georgakoudi, I., B.C. Jacobson, J. Van Dam, et al 2001. Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology 120: 16.
47. Prasad, G.A., A. Bansal, P. Sharma & K.K. Wang 2010. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am. J. Gastroenterology 105: 1490-1502.
48. Junttila, M.R. & G.I. Evan 2009. p53-a Jack of all trades but master of none. Nat. Rev. Cancer 9: 821-829.
49. Schneider, P.M., A.G. Casson, B. Levin, et al 1996. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J. Thorac. Cardiovasc. Surg. 111: 323-331; discussion 331-3.
50. Madani, K., R. Zhao, H.J. Lim & A.G. Casson 2010. Prognostic value of p53 mutations in esophageal adenocarcinoma: final results of a 15-year prospective study. Eur. J. Cardiothorac. Surg. 37: 1427-1432.
51. Schneider, P.M., O. Stoeltzing, J.A. Roth, et al 2000. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin. Cancer Res. 6: 3153-3158.
52. Younes, M., R.M. Lebovitz, L.V. Lechago & J. Lechago 1993. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 105: 1637-1642.
53. Weston, A.P., S.K. Banerjee, P. Sharma, et al 2001. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 96: 1355-1362.
54. Murray, L., A. Sedo, M. Scott, et al 2006. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 55: 1390-1397.
55. Giménez, A., A. Minguela, P. Parrilla, et al 1998. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus. Cancer 83: 641-651.
56. Wong, D.J., T.G. Paulson, L.J. Prevo, et al 2001. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 61: 8284-8289.
57. Maley, C.C., P.C. Galipeau, X. Li, et al 2004. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 64: 3414-3427.
58. Galipeau, P.C., D.S. Cowan, C.A. Sanchez, et al 1996. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc. Natl. Acad. Sci. U S A 93: 7081-7084.